MX2009004081A - Metodo para restaurar el efecto de incretina. - Google Patents
Metodo para restaurar el efecto de incretina.Info
- Publication number
- MX2009004081A MX2009004081A MX2009004081A MX2009004081A MX2009004081A MX 2009004081 A MX2009004081 A MX 2009004081A MX 2009004081 A MX2009004081 A MX 2009004081A MX 2009004081 A MX2009004081 A MX 2009004081A MX 2009004081 A MX2009004081 A MX 2009004081A
- Authority
- MX
- Mexico
- Prior art keywords
- restoring
- methods
- present
- insulin secretion
- incretin effect
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se relaciona con métodos para tratar el síndrome metabólico, diabetes mellitus Tipo II, dislipidemia aterogénica y/u obesidad. La presente invención también se relaciona con métodos para restaurar el efecto de incretina, para restaurar el control fisiológico de niveles de glucagón, para restaurar la secreción de insulina de primera fase y restaurar la secreción de insulina dependiente de glucosa fisiológica. Los métodos de la presente invención comprenden la administración de un antagonista ic-receptor selectivo, tal como naltrindol guanidinilatado (GLTI), o derivados farmacéuticamente aceptados de los mismos a un sujeto con necesidad de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86222706P | 2006-10-20 | 2006-10-20 | |
PCT/US2007/082084 WO2008051902A2 (en) | 2006-10-20 | 2007-10-22 | Method of restoring the incretin effect |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009004081A true MX2009004081A (es) | 2009-06-18 |
Family
ID=39325299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009004081A MX2009004081A (es) | 2006-10-20 | 2007-10-22 | Metodo para restaurar el efecto de incretina. |
Country Status (9)
Country | Link |
---|---|
US (8) | US7893080B2 (es) |
EP (2) | EP2724722B1 (es) |
BR (1) | BRPI0718420A2 (es) |
CA (1) | CA2666846C (es) |
ES (1) | ES2618500T3 (es) |
MX (1) | MX2009004081A (es) |
PT (1) | PT2724722T (es) |
SI (1) | SI2724722T1 (es) |
WO (1) | WO2008051902A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7893080B2 (en) | 2006-10-20 | 2011-02-22 | Neurendo Pharma, Llc | Method of restoring the incretin effect |
CN102753526B (zh) * | 2009-12-07 | 2014-11-26 | 佐治亚大学研究基金会 | 吡啶酮羟基环戊基羧酰胺:具有治疗用途的hiv 整合酶抑制剂 |
US10034871B2 (en) | 2014-11-07 | 2018-07-31 | Regents Of The University Of Minnesota | Salts and compositions useful for treating disease |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4272540A (en) | 1979-04-24 | 1981-06-09 | Sisa, Incorporated | 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them |
IE51145B1 (en) | 1980-03-07 | 1986-10-15 | Efamol Ltd | Pharmaceutical and dietary compositions |
US4451470A (en) | 1982-07-06 | 1984-05-29 | E. I. Du Pont De Nemours And Company | Analgesic, antagonist, and/or anorectic 14-fluoromorphinans |
HU201675B (en) | 1983-08-26 | 1990-12-28 | Ivan Balkanyi | Process for producing oral pharmaceutical compositions with unappetizing effect |
US4478840A (en) | 1983-10-11 | 1984-10-23 | E. I. Du Pont De Nemours And Company | Appetite suppressing compositions and methods |
US5208250A (en) | 1988-05-25 | 1993-05-04 | Warner-Lambert Company | Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents |
US4882335A (en) | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
US5428066A (en) | 1989-03-08 | 1995-06-27 | Larner; Joseph | Method of reducing elevated blood sugar in humans |
US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
US5843089A (en) | 1990-12-28 | 1998-12-01 | Boston Scientific Corporation | Stent lining |
US5086058A (en) | 1990-06-04 | 1992-02-04 | Alko Ltd. | Method for treating alcoholism with nalmefene |
WO1993000337A1 (de) * | 1991-06-21 | 1993-01-07 | Dr. Karl Thomae Gmbh | (s)(+)-2-äthoxy-4-[n-[1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]-benzoesäure |
US5866595A (en) | 1991-09-26 | 1999-02-02 | The Regents Of The University Of California | Calcium antagonists for treatment of vascular restenosis |
DE4136215A1 (de) | 1991-11-02 | 1993-05-06 | Ferring Arzneimittel Gmbh, 2300 Kiel, De | Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie |
US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
US5772629A (en) | 1995-10-23 | 1998-06-30 | Localmed, Inc. | Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels |
WO1997018781A1 (en) | 1995-11-20 | 1997-05-29 | University Of Miami | Method of treating nicotine dependence |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
GB9606076D0 (en) | 1996-03-22 | 1996-05-22 | Univ Birmingham | Diabetes treatment |
EP0906091B1 (en) | 1996-03-29 | 2006-10-04 | Ortho-McNeil Pharmaceuticals, Inc. | Amidinohydrazones as protease inhibitors |
US6294559B1 (en) | 1996-05-02 | 2001-09-25 | Merck & Co., Inc. | Antiproliferative agents associated with peroxisome proliferator activated receptors gamma1 and gamma2 |
US6387121B1 (en) | 1996-10-21 | 2002-05-14 | Inflow Dynamics Inc. | Vascular and endoluminal stents with improved coatings |
US5727570A (en) | 1996-11-14 | 1998-03-17 | Clemens; Anton H. | Method of treating hyperlipidemia in humans |
US6026817A (en) | 1996-11-14 | 2000-02-22 | Clemens; Anton H. | Method of treating the syndrome of coronary heart disease risk factors in humans |
US5878750A (en) | 1996-11-14 | 1999-03-09 | Clemens; Anton H. | Method of treating the syndrome of coronary heart disease risk factors in humans |
US5925657A (en) | 1997-06-18 | 1999-07-20 | The General Hospital Corporation | Use of PPARγ agonists for inhibition of inflammatory cytokine production |
US6103722A (en) | 1997-07-23 | 2000-08-15 | The Medical College Of Wisconsin Research Foundation Inc. | Ischemic preconditioning |
US6242196B1 (en) | 1997-12-11 | 2001-06-05 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
KR100620935B1 (ko) | 1998-03-19 | 2006-09-13 | 브리스톨-마이어스스퀴브컴파니 | 용해도가 높은 약물에 대한 2상 서방성 전달 시스템과 방법 |
WO1999058120A1 (en) | 1998-05-08 | 1999-11-18 | Rolf Berge | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS |
JP2002515503A (ja) | 1998-05-18 | 2002-05-28 | ノボ ノルディスク アクティーゼルスカブ | オピオイド受容体のサブタイプへの高い親和性を有する新規1,3,8−トリアザスピロ〔4,5〕デカノン |
US6280411B1 (en) | 1998-05-18 | 2001-08-28 | Scimed Life Systems, Inc. | Localized delivery of drug agents |
US6369039B1 (en) | 1998-06-30 | 2002-04-09 | Scimed Life Sytems, Inc. | High efficiency local drug delivery |
AU5344799A (en) | 1998-08-06 | 2000-02-28 | Robert M Jones | Kappa (op2) opioid receptor antagonists |
AU6184499A (en) | 1998-10-28 | 2000-05-15 | University Of British Columbia, The | Organic vanadium(iii) complexes and their use |
US6087385A (en) | 1998-10-30 | 2000-07-11 | University Of Mississippi | Flavonoid derivatives |
US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
ATE384035T1 (de) | 1999-04-01 | 2008-02-15 | Esperion Therapeutics Inc | Ether-verbindungen, zusammensetzungen und ihre verwendung |
US6458952B1 (en) | 1999-05-19 | 2002-10-01 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US6309660B1 (en) | 1999-07-28 | 2001-10-30 | Edwards Lifesciences Corp. | Universal biocompatible coating platform for medical devices |
US6471979B2 (en) | 1999-12-29 | 2002-10-29 | Estrogen Vascular Technology, Llc | Apparatus and method for delivering compounds to a living organism |
US6528520B2 (en) * | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
WO2002013759A2 (en) * | 2000-08-15 | 2002-02-21 | Cpd Llc | Method of treating the syndrome of type 2 diabetes in humans |
US6846831B2 (en) | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
US20020045572A1 (en) * | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
US6262062B1 (en) | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
US6910310B2 (en) | 2002-09-03 | 2005-06-28 | Braided Accents Llc | Chair rail system and method |
US7893080B2 (en) * | 2006-10-20 | 2011-02-22 | Neurendo Pharma, Llc | Method of restoring the incretin effect |
-
2007
- 2007-10-22 US US11/876,279 patent/US7893080B2/en not_active Expired - Fee Related
- 2007-10-22 EP EP13197508.8A patent/EP2724722B1/en not_active Not-in-force
- 2007-10-22 SI SI200731903A patent/SI2724722T1/sl unknown
- 2007-10-22 ES ES13197508.8T patent/ES2618500T3/es active Active
- 2007-10-22 PT PT131975088T patent/PT2724722T/pt unknown
- 2007-10-22 WO PCT/US2007/082084 patent/WO2008051902A2/en active Application Filing
- 2007-10-22 BR BRPI0718420-4A2A patent/BRPI0718420A2/pt not_active Application Discontinuation
- 2007-10-22 MX MX2009004081A patent/MX2009004081A/es active IP Right Grant
- 2007-10-22 CA CA2666846A patent/CA2666846C/en not_active Expired - Fee Related
- 2007-10-22 EP EP07844505A patent/EP2083817A4/en not_active Withdrawn
-
2010
- 2010-10-18 US US12/906,735 patent/US8445508B2/en not_active Expired - Fee Related
- 2010-10-18 US US12/906,740 patent/US8399474B2/en not_active Expired - Fee Related
-
2013
- 2013-02-22 US US13/774,388 patent/US8785469B2/en not_active Expired - Fee Related
- 2013-04-10 US US13/859,940 patent/US8829018B2/en not_active Expired - Fee Related
-
2014
- 2014-07-18 US US14/335,155 patent/US20140329844A1/en not_active Abandoned
- 2014-09-08 US US14/479,828 patent/US9987268B2/en not_active Expired - Fee Related
-
2018
- 2018-06-05 US US15/997,965 patent/US20190134023A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2618500T3 (es) | 2017-06-21 |
US20080108640A1 (en) | 2008-05-08 |
US9987268B2 (en) | 2018-06-05 |
BRPI0718420A2 (pt) | 2013-11-12 |
WO2008051902A3 (en) | 2008-07-10 |
CA2666846A1 (en) | 2008-05-02 |
US20110118293A1 (en) | 2011-05-19 |
EP2083817A2 (en) | 2009-08-05 |
US7893080B2 (en) | 2011-02-22 |
US20130172380A1 (en) | 2013-07-04 |
EP2724722B1 (en) | 2016-12-07 |
EP2724722A1 (en) | 2014-04-30 |
US20140329844A1 (en) | 2014-11-06 |
US20130224176A1 (en) | 2013-08-29 |
CA2666846C (en) | 2018-04-10 |
US20150065535A1 (en) | 2015-03-05 |
US8785469B2 (en) | 2014-07-22 |
SI2724722T1 (sl) | 2017-07-31 |
WO2008051902A2 (en) | 2008-05-02 |
US8445508B2 (en) | 2013-05-21 |
US8829018B2 (en) | 2014-09-09 |
US8399474B2 (en) | 2013-03-19 |
EP2083817A4 (en) | 2009-12-23 |
PT2724722T (pt) | 2017-03-14 |
US20110034501A1 (en) | 2011-02-10 |
US20190134023A1 (en) | 2019-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA89615C2 (ru) | Фармацевтические композиции, которые содержат никотиновую кислоту и антагонист рецептора dp | |
WO2006086107A3 (en) | Methods and compositions for minimizing accrual of inhalable insulin in the lungs | |
WO2007111864A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
UA96308C2 (ru) | Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение | |
WO2004056317A3 (en) | Compositions for the treatment and prevention of nephropathy | |
HK1046105A1 (zh) | 抑制胰高血糖素的方法 | |
Henry et al. | Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers | |
TNSN07080A1 (en) | Method of assembly of drug delivery devices | |
WO2004000354A3 (en) | Method of treating the syndrome of lipodystrophy | |
MXPA05006994A (es) | Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina. | |
WO2007111945A3 (en) | Method for management of diarrhea | |
IL168056A0 (en) | Selected cgrp antagonists, method for production and use thereof as medicament | |
MX2008013304A (es) | Compuestos de peptido 1 tipo glucagon. | |
PL376373A1 (en) | Selected cgrp antagonists, method for production and use thereof as medicament | |
TW200733971A (en) | CGRP peptide antagonists and conjugates | |
WO2005123109A3 (en) | Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use | |
WO2006047392A3 (en) | Nicotinic-opioid synergy for analgesia | |
WO2004050115A3 (en) | Combination treatment using exendin-4 and thiazolidinediones | |
WO2006050002A3 (en) | Compositions for controlled delivery of pharmaceutically active compounds | |
WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
CY1110152T1 (el) | Χρηση συνδυασμου μορφινης και τουλαχιστον ενος ανταγωνιστη φυσικου οπιοειδους στην αγωγη της εξαρτησης απο φυσικα οπιοειδη και στην προληψη της μη στοματικης καταχρησης φυσικων οπιοειδων σε εξαρτημενους απο φυσικα οπιοειδη | |
MX2009004081A (es) | Metodo para restaurar el efecto de incretina. | |
WO2005067548A3 (en) | Use of ribose in recovery from anaesthesia | |
AU2012207301A8 (en) | Apolipoprotein AIV as an antidiabetic peptide | |
IL182135A0 (en) | Liquid allergy vaccine formulation for ormucosal administration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
GB | Transfer or rights | ||
FG | Grant or registration |